• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, June 25, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Synergistic immunotherapy approach offers improved efficacy in eliminating tumors

Bioengineer by Bioengineer
April 24, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Radiation and chemotherapy treatments for cancers destroy tumors and healthy tissue alike, often leading to severe side effects. Cancer immunotherapy approaches, which stimulate the immune system to selectively attack tumor cells, represent an opportunity to treat cancer without harming healthy cells.

While immunotherapy approaches have been successful against hematological malignancies, they have been less effective in eradicating solid tumors. This is partially due to the ability of tumors to suppress local immune responses. A major goal of cancer immunotherapies that are in development has been to improve the targeting of solid tumors.

A team led by Matthias Stephan at the Fred Hutchinson Cancer Research Center has developed a biopolymer delivery system that combines two synergistic immunotherapy approaches: CAR T cells (immune cells that are reprogrammed to target tumors), and STING agonists, which stimulate the innate immune system. In a study published this week in the JCI, they show that this method of activating the immune system at the site of CAR T cell delivery eliminates tumors more effectively than CAR T cell therapy alone.

The researchers implanted a biopolymer scaffold to co-deliver STING agonists and CAR T cells to tumor sites in a mouse model of pancreatic cancer and melanoma. The STING agonists improved the function of CAR T cells compared to CAR T cells that were delivered alone. However, the STING agonists also triggered anti-tumor responses within the mice that prevented tumor metastasis. These findings provide promising support for combined immunotherapy approaches for treating solid cancers.

###

TITLE: Biopolymers co-delivering engineered T cells and STING agonists can eliminate heterogeneous tumors

AUTHOR CONTACT:

Matthias Stephan
Fred Hutchinson Cancer Research Center
[email protected]

View this article at: http://www.jci.org/articles/view/87624?key=a99e94835f02ba7b53e2

Media Contact

Elyse Dankoski
[email protected]
@jclinicalinvest

http://www.jci.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

June 25, 2026

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

June 25, 2026

Natural Hallucinogens: Evolution’s Ecological Tools, Not Mere Chemical Byproducts

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.